TY  - JOUR
AU  - Mazieres, Julien
AU  - Kowalski, Dariusz
AU  - Luft, Alexander
AU  - Vicente, David
AU  - Tafreshi, Ali
AU  - Gümüş, Mahmut
AU  - Laktionov, Konstantin
AU  - Hermes, Barbara
AU  - Cicin, Irfan
AU  - Rodríguez-Cid, Jerónimo
AU  - Wilson, Jonathan
AU  - Kato, Terufumi
AU  - Ramlau, Rodryg
AU  - Novello, Silvia
AU  - Reddy, Sreekanth
AU  - Kopp, Hans-Georg
AU  - Piperdi, Bilal
AU  - Li, Xiaodong
AU  - Burke, Thomas
AU  - Paz-Ares, Luis
PY  - 2019
DO  - 10.1200/JCO.19.01348
UR  - http://hdl.handle.net/10668/14720
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - In the phase 3 KEYNOTE-407 study, the addition of pembrolizumab to carboplatin-paclitaxel/nab-paclitaxel significantly improved overall survival, progression-free survival, and objective response rate in patients with previously untreated metastatic...
LA  - en
KW  - Adult
KW  - Aged
KW  - Albumins
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carboplatin
KW  - Carcinoma, Squamous Cell
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Paclitaxel
KW  - Patient Reported Outcome Measures
KW  - Progression-Free Survival
KW  - Quality of Life
TI  - Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
TY  - research article
VL  - 38
ER  -